Mylan NV shares rose in the extended session Thursday after the drug maker said a Food and Drug Administration advisory committee recommended approval of its generic version of Roche’s breast-cancer drug Herceptin. Mylan shares rose 1.3% to $39.55 after hours. The FDA’s Oncologic Drugs Advisory Committee voted 16 to 0 recommending that the agency approve trastuzumab, a biologically similar version of Roche’s breast-cancer drug Herceptin, Mylan said. Mylan and partner Biocon Ltd., based in Bengaluru, India, developed the drug. The FDA is not obligated to follow the recommendations of its advisory committees but generally does.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News